Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials
The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia.
Databases including MEDLINE, EMBASE, ISI web of knowledge, the Cochrane Controlled Trial Register of Controlled Trials and Chinese Biological Medical Database were searched to identify randomized controlled trials (RCTs) that referred to the efficacy and safety of desmopressin for the treatment of nocturia. A systematic review and meta-analysis were conducted.
Five studies involving 619 participants were included for the meta-analysis, and 8 RCTs of cross-over design were also identified for the systematic review. The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids, nocturnal urine volume and nocturnal diuresis, potentially resulting in an extended duration of the first sleep period and improved sleep quality. The adverse effects of desmopressin were similar to those observed in the placebo group.
Administered desmopressin was an effective and well-tolerated treatment for nocturia.
KeywordsDesmopressin Nocturia Nocturnal polyuria Efficacy Safety
We thank American Journal Experts for assisting in the preparation of this manuscript.
Conflict of interest
The authors had no conflicts of interest to declare in relation to this article.
- 1.van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, Jennum P, Johnson T, Lose G, Mattiasson A, Robertson G, Weiss J (2002) The standardisation of terminology in nocturia: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183PubMedCrossRefGoogle Scholar
- 26.Maserejian NN, Kupelian V, Link CL, McKinlay JB (2011) Modifiable lifestyle behaviors and incidence of lower urinary tract symptoms and urine leakage in a population-based study of men and women. J Urol (Suppl) 185:e18Google Scholar
- 27.Vilhardt H (1990) Basic pharmacology of desmopressin: a review. Drug Invest (Suppl) 2:2–8Google Scholar